<DOC>
	<DOCNO>NCT00627458</DOCNO>
	<brief_summary>The purpose booster study evaluate , subject prim primary study 106786 , persistence , time booster vaccination , antibody elicit different formulation DTPa-HBV-IPV/ Hib vaccine ( Infanrix Hexa TM ) . The study also evaluate immune response subject DTPa-HBV-IPV/Hib booster . This protocol post deal objectives outcome measure booster phase . The objective outcomes measure primary phase present separate protocol posting ( NCT = 00376779 ) .</brief_summary>
	<brief_title>Immunogenicity Reactogenicity Booster Dose GSK Bio 's DTPa-HBV-IPV/Hib Vaccine</brief_title>
	<detailed_description>This protocol post updated order comply FDA AA , Sep 2007 .</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parents/guardians comply requirement protocol Subjects must complete full threedose primary vaccination course one formulation DTPaHBVIPV/Hib vaccine primary study 106786 . A male female , include , 16 20 month age time booster vaccination . Written inform consent obtain parent guardian subject Healthy subject establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) study vaccine within 30 day precede booster dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior booster vaccine dose . Participation another clinical study , primary study 106786 present booster study , time study , subject expose investigational noninvestigational product . Planned administration administration vaccine foreseen study protocol period start 30 day administration booster dose end 30 day booster dose . Evidence previous diphtheria , tetanus , pertussis , polio , hepatitis B and/or Hib booster vaccination disease since conclusion visit study 106786 . Any confirmed suspected immunosuppressive immunodeficient condition , base physical examination . History allergic disease reaction likely exacerbate component vaccine . Acute disease time enrolment . Administration immunoglobulins and/or blood product within three month precede booster dose plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>16 Months</minimum_age>
	<maximum_age>20 Months</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hexavalent vaccine</keyword>
	<keyword>Booster</keyword>
</DOC>